Hypercalcemia in an euthyroid patient with secondary hypoadrenalism and diabetes insipidus due to hypothalamic tumor.
A 20-year-old Japanese man with a hypothalamic tumor (most likely germ-cell tumor) which caused secondary hypoadrenalism, hypogonadism and diabetes insipidus developed hypercalcemia and acute renal failure. The serum levels of intact PTH (iPTH), PTH-related protein (PTH-rP), 1,25-dihydroxy vitamin D (1,25- (OH)2 D), ACTH, cortisol, gonadotropins and testosterone were decreased, but his serum levels of triiodothyronine (T3) and thyroxine (T4) were within the normal range at admission, with depressed TSH and slightly increased thyroglobulin. The hypercalcemia was refractory to extensive hydration and calcitonin, but was ameliorated by pamidronate. After irradiation of the hypothalamic tumor, panhypopituitarism gradually developed. The patient has been normocalcemic for the last 2 years and is doing well under replacement therapy with glucocorticoid, L-thyroxine, methyltestosterone and 1-desamino D arginine vasopressin (dDAVP). As to the mechanism of euthyroidism at admission, transient destructive thyroiditis associated with hypopituitarism or delayed development of hypothyroidism following the hypoadrenalism was suggested. This is the first reported case of hypercalcemia in secondary hypoadrenalism due to hypothalamic tumor. Hypercalcemia was most likely induced by increased bone resorption, which was probably elicited by the combined effects of deficient glucocorticoid and sufficient thyroid hormones in addition to hypovolemia and reduced renal calcium excretion. Furthermore, severe dehydration due to diabetes insipidus and disturbance of thirst sensation caused by the hypothalamic tumor aggravated the hypercalcemia, leading to acute renal failure.
Hotta
M
M
Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University School of Medicine, Japan.
Sato
K
K
Shibasaki
T
T
Demura
H
H
D058186:Acute Kidney Injury / Q000209:etiology; D000309:Adrenal Insufficiency / Q000097:blood / Q000209:etiology*; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003919:Diabetes Insipidus / Q000097:blood / Q000209:etiology*; D004164:Diphosphonates / Q000627:therapeutic use; D006212:Hallucinations / Q000097:blood / Q000209:etiology*; D006801:Humans; D006934:Hypercalcemia / Q000150:complications* / Q000188:drug therapy; D007029:Hypothalamic Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000532:radiotherapy; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000150:complications / Q000175:diagnosis / Q000532:radiotherapy; D000077268:Pamidronate
D000970:Antineoplastic Agents; D004164:Diphosphonates; D000077268:Pamidronate